MarketLens
Sign Up

What's Behind Regenxbio's Recent Plunge

7 months ago
SHARE THIS ON:

What's Behind Regenxbio's Recent Plunge

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•1 months ago

Is Regeneron Stock a Bargain Below $800?

Regeneron reported strong financial results and is finding ways to overcome a recent patent cliff, with shares trading below $800. The company's ability to offset lost revenue will determine whether t...
Stock News•1 months ago

Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial

Regenxbio shares fell 22% after discovering nodules and masses on spines of patients in its RGX-121 gene therapy trial for Hunter syndrome, raising safety concerns.
Stock News•2 months ago

Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimates

Regenxbio (RGNX) reported Q2 EPS of $0.43, beating the $0.12 consensus and swinging from a $1.38 loss a year ago, after stronger-than-expected revenue.

Breaking News

View All →

Top Headlines

View More →
Stock News•1 hour ago

Farkas Says Starlink Slowdown Helped the Russians

Stock News•1 hour ago

Amazon (AMZN) Suffers a Larger Drop Than the General Market: Key Insights

Stock News•1 hour ago

Here's Why Dell Technologies (DELL) Fell More Than Broader Market

Stock News•1 hour ago

Microsoft (MSFT) Falls More Steeply Than Broader Market: What Investors Need to Know

Stock News•1 hour ago

Elon Musk's Tesla eyes transportation ‘domination' as Cybercab expansion heats up competition with Waymo